Search the Newsreel

Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX

Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in the second quarter, valued at approximately $3.57 million. Other hedge funds also adjusted their holdings, with institutional investors now owning 90.96% of the stock. Analysts currently have a "Moderate Buy" rating for VRTX …

Occidental Petroleum Corporation $OXY Shares Bought by TD Asset Management Inc

TD Asset Management Inc. significantly increased its holdings in Occidental Petroleum Corporation (NYSE:OXY) by 47.5% in the second quarter of 2026, acquiring an additional 229,782 shares, bringing its total to 713,272 shares valued at approximately $34.6 million. This comes after Occidental Petroleum reported strong …

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments

Summit Global Investments acquired 7,506 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at $4.68 million during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with $14.29 EPS and $4.29 billion in revenue, representing a 16.7% year-over-year increase. Despite a "Moderate Buy" consensus …

Walleye Trading LLC Makes New Investment in Euronet Worldwide, Inc. $EEFT

Walleye Trading LLC has made a new investment in Euronet Worldwide (NASDAQ:EEFT), purchasing 14,588 shares valued at approximately $1.07 million. Other institutional investors also adjusted their holdings, with a significant 91.6% of the stock owned by institutional investors and hedge funds. Analyst sentiment for …

Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a …

Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock

An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.

Qsemble Capital Management LP Reduces Stock Position in Occidental Petroleum Corporation $OXY

Qsemble Capital Management LP significantly reduced its stake in Occidental Petroleum Corporation by 65.1% in the second quarter, selling 127,456 shares and retaining 68,415 shares valued at approximately $3.3 million. Despite this reduction, institutional investors collectively still own 88.7% of OXY. The company recently …

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"

Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share …

Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Zacks Research downgraded Monopar Therapeutics (NASDAQ:MNPR) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "moderate buy" with an average price target of $117.42. The company's shares opened at $113.04, trading near their 12-month high, and it recently reported …

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

GMAT3 - Grupo Mateus - Resultados, Dividendos, Cotação e Indicadores

Markel Group Inc. Grows Stake in Weyerhaeuser Company $WY

Markel Group Inc. significantly increased its stake in Weyerhaeuser Company by 585.7% in the second quarter, now holding 120,000 shares valued at $2,873,000. Other institutional investors also adjusted their holdings in Weyerhaeuser, which saw its stock trading down slightly at $24.55. The company recently …

Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP

Walleye Capital LLC has acquired a new position in Rapport Therapeutics, purchasing 102,163 shares valued at $4.26 million, representing 0.21% of the company. Despite the stock opening near its 52-week high, Rapport Therapeutics reported a quarterly loss of $1.19 per share, missing estimates. Analysts …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Levin Capital Strategies L.P. Invests $2.25 Million in Weyerhaeuser Company $WY

Levin Capital Strategies L.P. has acquired a new stake of 94,000 shares, valued at $2.25 million, in Weyerhaeuser Company (NYSE:WY) during the second quarter. Other institutional investors have also adjusted their holdings in the company. Wall Street analysts currently have a "Moderate Buy" rating …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

Pictet Asset Management Holding SA Sells 570,173 Shares of Weyerhaeuser Company $WY

Pictet Asset Management Holding SA reduced its stake in Weyerhaeuser Company (NYSE:WY) by 11.8% in the second quarter, selling 570,173 shares, but still holds 4.28 million shares valued at over $102 million. Analysts maintain a "Moderate Buy" rating for Weyerhaeuser with an average price …

128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …

Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO

Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics …

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from …

How (ADXN) Movements Inform Risk Allocation Models

This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting a positive near-term sentiment but broader weak alignment. It presents an exceptional 60.0:1 risk-reward setup targeting a 20.6% gain against a 0.3% risk. The article outlines institutional trading strategies, including position trading, momentum breakout, and …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Deutsche Bank Aktiengesellschaft Reiterates Sell Rating for Antofagasta (LON:ANTO)

Deutsche Bank Aktiengesellschaft has reissued a "sell" rating for Antofagasta (LON:ANTO), setting a price target of GBX 3,400, which suggests a potential downside of 5.92%. This rating contributes to an overall "Reduce" consensus among analysts, with an average price target of GBX 3,843.75. The …

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

C4 Therapeutics (CCCC) gains 6.9% disclosed stake from Squadron Master Fund

Squadron Master Fund LP and related entities have disclosed a 6.9% beneficial ownership stake in C4 Therapeutics (CCCC), totaling 7,600,000 shares. This includes 7,200,000 common shares and 400,000 shares underlying currently exercisable long call options. The filing indicates shared voting and dispositive powers among …

Coeur Mining, Inc. $CDE Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC significantly reduced its stake in Coeur Mining (NYSE:CDE) by 60% in the first quarter, selling 172,952 shares and retaining 115,143 shares. Despite this, institutional investors collectively own 63.01% of the company. Coeur Mining reported quarterly earnings that missed analyst expectations, though …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen has downgraded Protara Therapeutics (NASDAQ:TARA) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an average price target of $26.25. The company's shares were trading at $3.97, near their 52-week low, after reporting …

NewEdge Advisors LLC Raises Stake in Weyerhaeuser Company $WY

NewEdge Advisors LLC significantly increased its stake in Weyerhaeuser Company (NYSE:WY) by 317.4% in the first quarter, now holding 89,800 shares valued at $2.19 million. Institutional investors collectively own a substantial 82.99% of the company. Weyerhaeuser reported strong Q1 earnings, surpassing analyst estimates with …